Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Sinemet Cr

Sinemet Cr
In stock
25/100mg
from 38,22 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
45,86 £38,22 £
1,27 £ per tablet

In brief

  • Sinemet CR is a prescription-only medicine (POM) in the UK and should be dispensed with a prescription.
  • Sinemet CR is used to treat idiopathic Parkinson’s disease and motor fluctuations (“off” periods). Levodopa is converted to dopamine in the brain to replace deficient dopamine, while carbidopa inhibits peripheral levodopa decarboxylation to increase central availability and reduce peripheral side effects; the CR formulation provides sustained dopaminergic coverage.
  • Usual dosing starts with one 50 mg/200 mg tablet every 6–8 hours with careful titration to effect; a 25 mg/100 mg “half” formulation is also available for lower doses. Doses are adjusted individually and total daily levodopa is often kept below about 1,600 mg (up to ~8 tablets of 200 mg levodopa equivalent), under medical supervision.
  • Administered orally as modified‑release (prolonged/retard/polymer‑matrix) tablets; swallow whole unless the tablet is scored and a split is authorised—do not crush or chew CR tablets.
  • Initial effects are typically noticeable within about 30–60 minutes, but onset is slower than immediate‑release levodopa and may vary between patients.
  • Duration of action is prolonged compared with immediate‑release formulations, commonly providing smoother symptom control for approximately 4–8 hours per dose depending on individual response and dose.
  • Avoid excessive alcohol; alcohol can worsen side effects (drowsiness, dizziness), may affect absorption and is not recommended while taking Sinemet CR.
  • The most common side effect is nausea; other frequent effects include dizziness, insomnia, dry mouth, anorexia, fatigue/somnolence and abnormal dreams, while dose‑related dyskinesia, hallucinations and orthostatic hypotension can occur.
  • Would you like to try Sinemet CR without a prescription?

Basic Sinemet CR information

  • INN (international nonproprietary name): Carbidopa and levodopa.
  • Brand names available in the United Kingdom: Sinemet CR — prolonged‑release tablets 50 mg carbidopa/200 mg levodopa and 25 mg/100 mg (Half Sinemet CR).
  • ATC code: N04BA02.
  • Forms and dosages: Modified‑release tablets 50 mg/200 mg (peach, oval, marked “521”) and 25 mg/100 mg (pink, oval, marked “601”); polymer‑based sustained‑release matrix.
  • Manufacturers in the United Kingdom: Merck Sharp & Dohme (MSD).
  • Registration status in the United Kingdom: Licensed by the MHRA as a prescription-only medicine.
  • OTC / Rx classification: Prescription-only medicine (POM).

Critical warnings and restrictions (safety first)

Sinemet CR (carbidopa with levodopa) is a prescription‑only prolonged‑release treatment for motor fluctuations in Parkinson’s disease.

Stop and seek urgent medical help if you notice signs of serious reactions such as severe confusion, high fever with rigidity, sudden severe dyskinesia, or chest pain.

  • Absolute contraindications:
    • Narrow‑angle glaucoma.
    • Known hypersensitivity to carbidopa, levodopa or excipients.
    • Use of non‑selective MAO inhibitors within the previous 14 days.
    • Melanoma or suspicious undiagnosed skin lesions.
  • Relative cautions:
    • Severe cardiovascular or pulmonary disease.
    • Endocrine disorders such as hyperthyroidism.
    • History of convulsions, peptic ulcers or psychiatric illness.
    • Open‑angle glaucoma — monitor intraocular pressure.

Report suspected adverse reactions via the MHRA Yellow Card scheme.

  • Immediate actions checklist:
    • Stop the medicine and call 999 for sudden collapse, severe breathing difficulty, chest pain, or loss of consciousness.
    • Contact your neurology team urgently for severe confusion, new psychosis, or abrupt and severe dyskinesia.
    • Seek urgent assessment for features suggestive of neuroleptic malignant syndrome (high fever, rigidity, autonomic instability).

Keep emergency contact details and a current medication list on a wallet card.

Sinemet CR must be prescribed and titrated by an experienced clinician and reviewed regularly under NHS neurology clinics.

High-risk groups (elderly, pregnancy, chronic illness)

  • Elderly patients are more sensitive to carbidopa/levodopa and commonly need lower starting doses and slower titration.
  • Children: use is not recommended owing to insufficient safety and efficacy data.
  • Pregnancy and breastfeeding: limited data; weigh risks and benefits with obstetrics and neurology.
  • Liver or renal impairment: use cautiously and monitor, since pharmacokinetics may alter.
  • Elderly: Start low, go slow; monitor for orthostatic hypotension, hallucinations and dyskinesia.
  • Pregnancy/breastfeeding: Individual risk/benefit discussion with obstetrician and neurologist required.
  • Liver/renal impairment: Increased monitoring; consider dose reduction if adverse effects emerge.
  • Risk: Higher sensitivity, orthostatic hypotension, psychosis risk.
  • Monitoring frequency: Medication review at least every 3–6 months for frail older adults; more frequently during titration.
  • Responsible clinician: Neurology for initiation and complex changes; GP for routine repeat prescribing with shared care as agreed.

Carers should keep a photocopied actionable plan showing dose times, what to do if a dose is missed, emergency symptoms to watch for, and the link for Yellow Card reporting.

Interaction with activities (driving, workplace safety under UK law)

Patients often ask if they can keep driving after starting Sinemet CR.

  • Levodopa preparations can cause dizziness, somnolence and sudden sleep episodes.
  • If medication or the underlying condition affects driving safety, patients must notify the DVLA under UK law.
  • Clinicians should document any advice given about driving in the medical record.
  • For work involving heights or vehicle operation, arrange a written risk assessment and consider occupational health referral.
  • Checklist for suspending driving:
    • Recurrent sudden sleepiness or ‘sleep attacks’.
    • Severe dizziness affecting attention or balance.
    • New‑onset psychosis, hallucinations or significant confusion.
  • Avoid alcohol and other sedating substances that may compound drowsiness.
  • Sustained‑release formulations may reduce ‘off’ periods but can still cause peak‑related drowsiness; counsel patients about dose timing around shifts.
  • Employers should be informed where safety‑critical roles are affected; occupational health should advise on fitness for work.

Q&A — Can I drive after taking it in the UK?

Possibly, only if you remain alert and free of problematic side effects.

If you have dizziness, excessive sleepiness, sudden sleep attacks, confusion or hallucinations, stop driving and inform the DVLA and your prescriber.

Ask your GP or neurologist for a documented fitness‑to‑drive assessment and keep a written record of any counselling.

Usage basics

INN, brand names available in the UK

  • INN: Carbidopa and levodopa.
  • UK brand: Sinemet CR, prolonged‑release tablets 50 mg/200 mg and 25 mg/100 mg (Half Sinemet CR).
  • Manufacturer: Originator Merck Sharp & Dohme (MSD); licensed generics available.
Strength Colour Marking MR delivery system
50 mg carbidopa / 200 mg levodopa Peach, oval Marked “521” Polymer‑based modified‑release matrix
25 mg carbidopa / 100 mg levodopa Pink, oval Marked “601” Polymer‑based modified‑release matrix
  • Alternate names patients may see: generic carbidopa/levodopa prolonged‑release, co‑careldopa MR, carbidopa levodopa MR.

Legal classification (POM, P, GSL)

  • Sinemet CR is prescription‑only (POM) across the UK.
  • Prescriptions are issued by GPs, neurology clinics or hospital specialists and increasingly via NHS e‑prescriptions.
  • Community pharmacies dispense on presentation of a valid prescription; private purchase without prescriber oversight is unsafe.
  • Pharmacists must provide counselling on dose, storage, interactions and safety, and record this in the pharmacy notes.
  • MHRA provides regulatory oversight and collects safety reports via the Yellow Card system.

Dosing guide

Standard regimens (NHS guidelines)

Patients commonly ask how to start Sinemet CR.

A typical initial titration is one 50/200 mg tablet every 6–8 hours, adjusted to clinical response.

Sinemet CR has lower bioavailability than immediate‑release formulations, so conversion is not mg‑for‑mg and requires careful up‑titration.

Stage Example dose Notes
Starting dose 50/200 mg once every 6–8 hours Increase slowly while monitoring response and side effects.
Usual maintenance Variable — often multiple tablets per day to control ‘off’ time Individualised to motor response and tolerability.
Maximum daily dose Approximately 8 tablets (1600 mg levodopa) Do not exceed without specialist oversight.
  • Titrate slowly and monitor for dyskinesia, orthostatic hypotension and psychiatric effects.
  • Schedule early follow‑up during titration and after dose changes.

Adjustments for comorbidities

  • Children: not recommended — insufficient data.
  • Elderly: start at the lowest effective dose and titrate more slowly; perform a falls‑risk assessment.
  • Liver or renal impairment: use cautiously; monitor clinical response and side effects.
  • Psychiatric disorders: consult psychiatry or neurology before initiation; may worsen psychosis.
  • Checklist for dose amendment triggers:
    • Emergence of severe side effects (marked dyskinesia, hallucinations).
    • Worsening renal or hepatic function.
    • Weight loss or malabsorption affecting response.
    • Addition of interacting medicines such as MAO inhibitors.

Document all dose changes on shared records held by primary care and neurology teams.

Q&A — What if I miss a dose?

Take the missed dose as soon as you remember unless it is near the next scheduled dose.

If it is near the next dose, skip the missed dose and resume the usual schedule.

Do not double up doses and do not crush prolonged‑release tablets to compensate; contact your prescriber if missed doses are frequent.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

Agent/food Effect Practical advice
High‑protein meals May reduce levodopa absorption and cause variable ‘on/off’ response Keep meal timing consistent; consider distributing protein away from dosing times.
Alcohol Can increase dizziness and sedation Advise moderation and avoid binge drinking when symptomatic.
Caffeine (tea/coffee) May worsen tremor or affect sleep in some patients Discuss individual effects and consider reducing intake if tremor or insomnia worsens.
  • Pharmacist‑led dietary counselling helps patients manage protein distribution to stabilise levodopa absorption.
  • Refer to dietetics for complex nutritional issues or weight loss affecting absorption.

Common drug conflicts

  • Non‑selective MAO inhibitors: contraindicated within 14 days — risk of severe hypertensive episodes.
  • Dopamine antagonists (many antipsychotics): may reduce levodopa efficacy and worsen motor control.
  • Iron and some mineral supplements: can reduce levodopa absorption; advise spacing doses.
  • Certain antidepressants require caution and specialist advice.
Drug/drug class Interaction type Action
Non‑selective MAOIs Severe hypertensive reactions Avoid; do not use within 14 days.
Antipsychotics (D2 antagonists) Reduced therapeutic effect Review psychiatric and neurology plan; consider alternative agents.
Iron supplements Reduced levodopa absorption Space administration by several hours.

Encourage Yellow Card reporting for suspected adverse drug interactions.

Legal status and availability in the UK

In our online pharmacy, Sinemet CR is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

  • Levodopa: A precursor to dopamine that crosses the blood–brain barrier to replenish central dopamine and improve motor symptoms.
  • Carbidopa: A peripheral dopa‑decarboxylase inhibitor that increases central levodopa availability and reduces peripheral side effects such as nausea.
  • CR matrix: A polymer‑based modified‑release system designed for sustained levodopa delivery to smooth dopaminergic coverage and reduce ‘off’ time.
  • ATC code: N04BA02 — combination carbidopa/levodopa.

Clinical terms

  • Bioavailability: CR has lower bioavailability than immediate‑release (IR), so higher total daily levodopa may be needed when switching.
  • On/off fluctuations: Periods when medication effect is present (‘on’) or absent (‘off’).
  • Dyskinesia: Involuntary movements, often dose‑related and more likely at higher cumulative levodopa exposure.
  • Peak‑dose effects: Symptoms or adverse effects that occur at the time of maximum plasma concentration.
  • Troughs: Symptoms returning as plasma levels fall before the next dose.
  • Titration: Gradual dose adjustment to balance benefit and side effects.
  • Monitoring parameters: Motor diary, lying/standing blood pressure, psychiatric screening, and renal/hepatic function where indicated.

Indications and off‑label uses

MHRA‑approved uses

  • Idiopathic Parkinson’s disease with motor fluctuations and ‘off’ periods where smoother prolonged coverage is clinically indicated.
  • Available in 50 mg/200 mg and 25 mg/100 mg strengths for tailored dosing.
  • Prescription and specialist oversight are required for initiation and switching regimens.

Off‑label practices in NHS and private care

  • Off‑label strategies may include bespoke schedules to manage severe dyskinesia under specialist supervision.
  • Occasional use in selected atypical parkinsonian presentations may occur with multidisciplinary agreement.
  • Combining with COMT inhibitors such as entacapone (as in Stalevo) is used when reduced ‘on’ time persists; document rationale and consent.
  • Always follow local governance, obtain informed consent and plan enhanced monitoring when using off‑label strategies.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Drug Formulation Pros Cons
Madopar HBS Benserazide/levodopa sustained‑release Alternative sustained release, benserazide instead of carbidopa. Variable efficacy; dyskinesia risk persists.
Stalevo Carbidopa/levodopa/entacapone COMT inhibition increases levodopa availability and on‑time. Additional side effects and interaction considerations.
Immediate‑release co‑careldopa IR tablets Better bioavailability per mg; easier to titrate rapidly. More frequent dosing; more pronounced peaks and troughs.
Generic CR formulations Carbidopa/levodopa extended‑release Similar sustained‑release options. Tablet markings and appearance may vary; check equivalence.
  • Decision factors include motor profile, prior levodopa response, cognitive/psychiatric status, comorbidities, polypharmacy risk and adherence ability.

Pros and cons checklist

  • Symptom pattern: Fluctuations benefit from CR; stable symptoms may be managed with IR.
  • Prior levodopa response: Good IR responders often benefit from CR smoothing.
  • Cognitive/psychiatric status: Avoid escalation if marked psychosis; consult specialists.
  • Comorbidities: Cardiac, hepatic or renal disease affects choice and monitoring.
  • Polypharmacy: Assess interaction risk before switching.
  • Adherence: CR can reduce dosing frequency but cannot be crushed to alter dose.
  • Switching notes: Overlap titration and specialist supervision advised; pharmacist to monitor and document.

Common questions

  • Will Sinemet CR stop my tremor?
    • Often reduces bradykinesia and rigidity; tremor response is variable and some patients still have residual tremor.
    • Action: Keep a motor diary and review with neurology if tremor persists.
  • Can I split tablets?
    • Do not crush CR tablets; only split along an authorised scoreline if manufacturer permits.
    • Action: Confirm tablet markings and advise against crushing to maintain modified release.
  • Is it interchangeable with IR Sinemet?
    • No — not mg‑for‑mg; conversion requires specialist supervision and careful titration.
    • Action: Refer to neurology for planned conversion and monitoring.
  • What long‑term monitoring is needed?
    • Monitor motor function, orthostatic blood pressure, mood and psychosis, and review dyskinesia regularly.
    • Action: Routine checks in neurology clinics and medication reviews in primary care.

Registration and regulation

MHRA approval process

  • Sinemet CR is a licensed prescription-only medicine in the UK under the MHRA framework.
  • Regulatory responsibilities include licence maintenance, periodic safety update reports and pharmacovigilance.
  • Post‑market surveillance is coordinated via Yellow Card reports and safety communications to prescribers and pharmacists.
  • Patient implications include updated patient information leaflets, potential recalls and guidance on reporting adverse reactions.

NHS prescribing framework

  • Prescribing requires an appropriate diagnosis and documentation of rationale for initiation or switching.
  • Shared care agreements should be used where specialist initiation passes routine prescribing to primary care.
  • Electronic prescribing workflows (FP10/e‑prescription) and medication review intervals must be followed.
  • Refer back to neurology when response is suboptimal, adverse effects emerge or dose ceilings are approached.
  • Follow local formulary guidance on product choice and substitution rules.

Storage and handling

UK household storage (cold/damp climate)

  • Store Sinemet CR below 25°C in its original packaging and protect from moisture.
  • Avoid storing in bathrooms or humid areas in UK households; use a dry cupboard instead.
  • Do not refrigerate or freeze; avoid prolonged exposure to heat.
  • Keep out of reach and sight of children and vulnerable adults.
  • Dispose of unused medicines via pharmacy returns — do not flush down the toilet.

Guidance from NHS and pharmacists

  • Pharmacists should counsel patients not to crush CR tablets and to check expiry dates on opened packs.
  • Document counselling in pharmacy records and provide printed or digital instructions for carers.
  • Advise safe transport of medication to clinics by keeping tablets in original packaging and avoiding extreme temperatures during travel.
  • Explain procedures for partial tablet disposal if splitting is authorised by the manufacturer.

Guidelines for proper use (practical patient and pharmacist checklist)

UK pharmacist counselling style

  • Confirm patient identity and the indication for Sinemet CR.
  • Review current symptom control and request a motor diary if available.
  • Explain differences between modified‑release and immediate‑release formulations.
  • Check interactions, allergies and other prescribed medicines.
  • Advise on storage, what to do if a dose is missed and the importance of not crushing tablets.
  • Discuss driving, work safety and document advice provided.
  • Provide a written action plan for carers including emergency contacts and Yellow Card link.

NHS patient safety advice

  • Carry a current medication list and note tablet markings and strengths (50/200 mg vs 25/100 mg).
  • Avoid crushing CR tablets and report mood or behaviour changes promptly.
  • Monitor for orthostatic symptoms with lying/standing blood pressures and report recurrent falls.
  • When to call 999: severe confusion, collapse, collapse with breathing difficulty or chest pain.
  • When to call GP/neurology: new hallucinations, worsening dyskinesia, recurrent falls or intolerable side effects.
  • Keep appointments for routine review and bring a motor diary to clinic visits.

Further NHS resources and patient leaflets are available from clinic teams and community pharmacists.

Delivery across the United Kingdom

City Region Delivery time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Leeds West Yorkshire 9–21 days
Glasgow Scotland 9–21 days
Edinburgh Scotland 9–21 days
Liverpool Merseyside 9–21 days
Bristol South West England 9–21 days
Sheffield South Yorkshire 9–21 days
Newcastle North East England 9–21 days
Nottingham East Midlands 9–21 days
Leicester East Midlands 9–21 days
Coventry West Midlands 9–21 days
Plymouth South West England 9–21 days
Portsmouth South East England 9–21 days

Related products